Home » Newsletters » BioWorld Science

BioWorld Science

July 27, 1999

View Archived Issues

Abbott makes major strides in R&D during Q2

Competitive Technologies' ribozymes offer promise in gene therapy approaches

Cerus initiates phase III U.S. trial of platelet pathogen inactivation system

Alza expands promotion of Ditropan XL for overactive bladder

Idec Pharmaceuticals development highlights during second quarter

AHP's pneumococcal conjugate vaccine receives priority review status

Clinical program initiated for CEP-1347 in neurodegenerative disease therapy

Fujisawa initiates enrollment in phase III RA trial of Prograf

Phase I trial results reported for MSI pulmonary delivery of morphine

Patient enrollment completed in Anogesic phase III trial

Progenics awarded two grants from NIH for HIV programs

Novel class of acetylcholine receptor ligands discovered by Sibia researchers

Cytokine production inhibitors from SB particularly useful for inflammation, osteoporosis

Chroman-based beta3-adrenoceptor agonists in development at Bayer

Novel BZ-site GABA-A receptor ligands disclosed by Sanofi-Synthelabo

New agents for glaucoma disclosed by Alcon in recent patent literature

Bayer presents new anticancer compounds that inhibit Raf kinase

Antiobesity compounds in the Novartis pipeline

Gacyclidine displays therapeutic window of up to one hour in rat model of focal cerebral ischemia

Dual antioxidant/nNOS inhibitor effective in animal models of cerebral ischemia and brain injury

Nitrosylated alpha-adrenoceptor antagonists as potential agents for impotence

FDA requests additional data to support n-docosanol NDA

BM-113: pharmacokinetics and metabolism in rats following oral and intravenous dosing

Magainin's Locilex cream not approvable says FDA

Elan to develop Antegren for chronic treatment of MS

Continuous infusion of toborinone preferable in heart failure developing after cardiac surgery

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...